Purple Biotech (PPBT) Net Income (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Net Income of -$89000.0 for Q1 2026, up 80.48% year-over-year from -$49312.3 in Q1 2025, and up 99.62% quarter-over-quarter from -$23.6 million in Q4 2025.
Purple Biotech (PPBT) Net Income (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Net Income for 13 consecutive years, with -$89000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 80.48% year-over-year to -$89000.0; the TTM figure through Mar 2026 stood at -$26.1 million (down 560.72% YoY), while the FY2025 annual figure was -$26.5 million, down 263.95% from the prior year.
- Net Income improved to -$89000.0 in Q1 2026 per PPBT's latest filing, from -$23.6 million in the prior quarter.
- Across five years, Net Income topped out at $15.1 million in Q4 2023 and bottomed at -$23.6 million in Q4 2025.
- Historically, Net Income has averaged -$2.6 million across 5 years, with a median of -$2.4 million in 2024.
- On a YoY basis, Net Income climbed as much as 1082.48% in 2022 and fell as far as 177500.0% in 2022.
- Purple Biotech's Net Income stood at $6.0 million in 2022, then surged by 151.34% to $15.1 million in 2023, then sank by 102.75% to -$415000.0 in 2024, then sank by 5596.87% to -$23.6 million in 2025, then jumped by 99.62% to -$89000.0 in 2026.
- Business Quant data shows PPBT's Net Income at -$89000.0 in Q1 2026, -$23.6 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,000.00 |
| Dec 31, 2025 | -23.64 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -456,000.00 |
| Dec 31, 2024 | -415,000.00 |
| Sep 30, 2024 | -668,000.00 |
| Jun 30, 2024 | -2.42 Mn |
| Mar 31, 2024 | -3.78 Mn |
| Dec 31, 2023 | 15.10 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -5.16 Mn |
| Mar 31, 2023 | -4.90 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | -4.85 Mn |
| Jun 30, 2022 | -3.55 Mn |
| Mar 31, 2022 | -7.32 Mn |
| Dec 31, 2021 | 508,000.00 |
| Sep 30, 2021 | 154,000.00 |
| Jun 30, 2021 | -2,000.00 |